June 12, 2020 / 10:14 AM / a month ago

BRIEF-Aprea Therapeutics Presents Results From French Phase IB/II Clinical Trial Of APR-246 (Eprenetapopt) And Azacitidine

June 12 (Reuters) - Aprea Therapeutics Inc:

* APREA THERAPEUTICS PRESENTS RESULTS FROM FRENCH PHASE IB/II CLINICAL TRIAL OF APR-246 (EPRENETAPOPT) AND AZACITIDINE IN PATIENTS WITH TP53 MUTANT MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA AT THE 25TH EUROPEAN HEMATOLOGY ASSOCIATION ANNUAL MEETI Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below